[Education] Multiple Myeloma: Top 10 Clinical Pearls

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Kirollos Hanna details the top ten clinical pearls for managing patients with multiple myeloma. Topics include the goals of therapy, the proper approach to treatment and transplant options, details of inhibitors and administration guidelines, the role of the pharmacist in managing complex regimens, and more.

 

In this episode you will learn:

 

Multiple Myeloma: Top 10 Clinical Pearls

• The goals of therapy regarding the disease state of multiple myeloma
• C.R.A.B. symptoms as the hallmark representation of multiple myeloma patients
• The approach to treatment and transplant options is based on various patient factors.
• The efficacy and complexities of triplet therapies
• Details of the three main proteasome inhibitors, administration guidelines, and common adverse reactions
• Approved immuno module drugs and their associated increased patient risk factors
• Highlighting the role of the pharmacist in managing complex regimens
• Novel upcoming mechanisms for managing multiple myeloma patients

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“It’s important to note that multiple myeloma remains, to date, an incurable disease.”
— Dr. Kirollos Hanna

 

“Proteasome inhibitors are indicated in numerous frontline and relapse refractory regimens in multiple myeloma, regardless of transplant eligibility.” — Dr. Kirollos Hanna

 

“Pharmacists really play an integral role in managing these patients.”  — Dr. Kirollos Hanna

 

“It’s likely that we will see some of these therapies come to light within the next several years for the multiple myeloma patient population.” — Dr. Kirollos Hanna